Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer : 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialGOGAS, Helen; DAFNI, Urania; CHRISTODOULOU, Christos et al.Breast cancer research and treatment. 2012, Vol 132, Num 2, pp 609-619, issn 0167-6806, 11 p.Article

Expression of Angiogenic Markers in the Peripheral Blood of Patients with Advanced Breast Cancer Treated with Weekly DocetaxelKORANTZIS, Ippokratis; KALOGERAS, Konstantine T; LINARDOU, Helena et al.Anticancer research. 2012, Vol 32, Num 10, pp 4569-4580, issn 0250-7005, 12 p.Article

Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancerRAZIS, Evangelia; DIMOPOULOS, Athanassios-Meletios; KOSMIDIS, Paris et al.Cancer investigation. 2001, Vol 19, Num 2, pp 137-144, issn 0735-7907Article

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFOSTIRA, Florentia; TSITLAIDOU, Marianthi; PAPAKOSTAS, Pavlos et al.Breast cancer research and treatment. 2012, Vol 134, Num 1, pp 353-362, issn 0167-6806, 10 p.Article

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trialKOSMIDIS, Paris; MYLONAKIS, Nick; PAPAKOSTAS, Pavlos et al.Journal of clinical oncology. 2002, Vol 20, Num 17, pp 3578-3585, issn 0732-183XArticle